Trial Profile
An observational multicenter/multiplatform study of direct oral anticoagulants in patients with atrial fibrillation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Oct 2016
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Thrombosis
- Focus Pharmacodynamics
- 24 Oct 2016 New trial record
- 27 Aug 2016 Results published in the Journal of Thrombosis and Haemostasis